Clinical Director, Neurology – Roche. Lead late-stage trials for Trontinemab in Alzheimer’s, shape strategy, and make real-world impact.

Job offer Mass Spectrometry Technology Specialist, Międzynarodowy Instytut Biologii Molekularnej i Komórkowej w Warszawie, Warszawa

I am so excited by this great new resource!    And not just because the most recent big paper purporting to do such a thing ( this one - s...

Among 1,767 patients in 5 centers, a fully automated blood test showed high accuracy for Alzheimer’s pathology in secondary and primary care using a predefined cutoff.

WHOOOOOOOOOOOOOOOOOOOOOOOOOOOOOAAAAAAAA!!!!! Dataset for reanalysis alert!!  Mann lab optimized perchlorate based enrichment to get a supe...

We are excited to announce DIA-NN 2.0, the most significant milestone in the history of DIA-NN development. Key Breakthroughs Proteoform Confidence mode: DIA-NN 2.0 solves the long-standing chall...

In an unprecedented move, research-grant reviews have been suspended indefinitely at the world’s largest public funder of biomedical research.

An ultra-low-input single-cell proteomic workflow is optimized to yield maximum proteome coverage with high accuracy and precision on the Orbitrap Astral mass spectrometer.

INTRODUCTION Alterations in locus coeruleus’ (LC) metabolic turnover are associated with Alzheimer's disease (AD)-pathology and cognitive impairment. However, the evolution of these changes across d...

Impaired cerebral glucose metabolism is a pathologic feature of Alzheimer’s disease (AD), with recent proteomic studies highlighting disrupted glial metabolism in AD. We report that inhibition of indo...

Impaired cerebral glucose metabolism is a pathologic feature of Alzheimer’s disease (AD), with recent proteomic studies highlighting disrupted glial metabolism in AD. We report that inhibition of indo...

In the Alzheimer's Association journal, authors discuss Public and Participant Involvement (PPI) and working with community members in dementia studies.